 Rich TV Live and we got some more big breaking news for you today. Today the news is from a Pharma Thayer Holdings, big breaking news from Pharma Thayer Holdings. Now, we're going to go into the news, but before we get into the news, I want to just show you guys a little bit about their website. The website is pharmathere.com, a clinical stage psychedelics biotech company. Here are the symbols, PHRF in America, PHRM in Canada, and you can go to the investor deck and learn more. So this is the website and all you got to do is click on news and there's a press release today that we're going to go through titled Pharma Thayer provides product pipeline updates and anticipated milestones for Q4 2021 and 2022. Let's talk about the key points of this press release. 10 clinical sites selected to participate in the FDA phase 2 clinical study evaluating ketamine for the treatment of Parkinson's disease. Initiated investigational new drug, IND application to proceed to a phase 2 clinical study for ketabit trademark to treat depression. Completed phase 2 clinical study protocol for ketamine to treat ALS for IND submission to the FDA. Near completion of research program to advance novel microneedle patches for the delivery of psychedelics, selected US-based CDMO to develop and supply proprietary ketamine products for FDA phase 3 clinical studies and commercialization and positioned ketamine focused product. Let's get back to that. Positioned ketamine focused product pipeline for potential phase 3 clinical studies and commercial supply in 2022. So lots of good news here for Pharma Thayer and they've been a big winner for our community. Congratulations to members on Pharma Thayer, PHRM in Canada on the Canadian Securities Exchange, PHRF on the OTC QB Exchange. Pharma Thayer Holding Zinc is a clinical stage psychedelics biotech company pleased to provide a product pipeline update and anticipated milestone for Q4 2021 and 2022 including ongoing FDA phase 2 clinical study programs, microneedle, microneedle patch delivery programs for psychedelics and clinical commercial manufacturing and supply for its proprietary ketamine and microneedle patch products. What does Fabio Cianelli have to say the chief executive officer of Pharma Thayer who we happen to have on our show first? I am very pleased with the progress of our clinical programs for ketamine as a potential treatment for Parkinson's disease, ALS, and depression. Our research programs for microneedle patch delivery are nearing completion and preparations for FDA phase 1 and 2 clinical studies are on track to support these and future programs. We are securing manufacturing and supply of our proprietary ketamine products and microneedle patches for plant FDA phase 2 and 3 clinical studies and commercialization in 2022 and beyond. We remain focused on achieving our milestones in Q4 2021 and building a solid foundation that will allow us to become a leader in the development and commercialization of novel ketamine based products. In addition, our interdermal delivery of ketamine and psychedelics via our proprietary microneedle patches position us for potential next generation therapeutic solution for mental health, neurological, and pain disorders. So they go through all of the areas of focus in this press release which I will go through. But before we do that, what I want to do is I just want to go through some of the key focus points which we're going to do right now. So right off the bat here, pharmacithera holdings, we're going to talk about the share structure. So right here on TMX money, you can see the share structure. So here's the share structure which I think is a very key element when I'm looking at a company. I'm always trying to understand their share structure, trying to always understand the fundamentals. 67 million shares ish in outstanding, still a 64 million market cap for this growing company. So good tight share structure which we love. We love a tight share structure. Now let's also look at the stock price. So we're going to take a look at Webull. This is Webull and you can see the share price right here and you can see the chart. So I've been talking about this company since it was at 10 cents in Canada, sorry, 10 cents in the US, been as high as $1.39 in the US, currently trading at 68 cents. That's PHRRF in America on the OTCQB exchange and in Canada, it's PHRM. You can see it's currently at 88 cents. I've always marked the high, high and the low, low, high, high currently at 124, the low, low at 18 and we're sitting right now at 88 cents. So clearly trend has been trending up. It did go to this higher level of 124 and retraced. So as an investor, you're always looking for a dip. You're always looking for a bottom to try to enter into this position. So these might be decent prices for pharma there, which has been clearly trending up. Good morning, Amanda. Amanda says much needed developments in the pain management sector. This is a huge market. Thank you very much for your message here, Amanda. I agree with you and pharma there has been a great winner. And to be honest with you, I don't think a lot of people even know them yet. So what we're going to do is we're going to go through this and we're going to watch them carefully and see if there's any spike whatsoever as this news starts to circulate. You can see that the average three month volume is 417,000 shares a day in Canada. Currently already sitting at 215,000 shares for the day. The market just getting started. So investors are starting to be aware of this news. It has been as high as 92 cents today, currently at 89. It opened at 89 when it's high as 92, as low as 83. So some investors did take profits today. Maybe they got in at 10 or 20 cents when this thing was really cheap. And they locked in some profits at 90, 92 cents, but it's sitting right now at 88 cents. If we go to the five day chart, you can see it's been trending down. We go to the one month chart. You can see that it had this nice move up. Now it's kind of trending down. So let's see if this news turns this around. Now I just want to go through this news a little bit in more detail. All right, let's just go through this news in more detail. So FDA phase two clinical study programs for the rest of 2021. Pharma Thayer will focus on advancing three promising developments through FDA phase two clinical studies. Ketamine for Parkinson's disease. The FDA is approved to proceed with the phase two clinical trial to evaluate the safety, efficacy, and pharma No, Caught genetics of ketamine in the treatment of lividopa induced Diskincia in patients with Parkinson's disease triggered clinical program execution. The company has completed its clinical trial startup activities and selection of essential vendors, including project management, central laboratory, clinical supply kits, and logistics, data management and biostatistics and clinical site management and monitoring. Clinical trial drug product ketamine and active placebo mydizolum have also been obtained. More importantly, the company has selected 10 clinical sites in the United States to participate in the phase two clinical study. Patient screening has begun and the company expects patient enrollment to support the delivery of clinical results in Q4 2021. For further details about the study, clinicaltrials.gov identifier NCT 049-12115 titled a multi-center phase two randomized double blind perspective active placebo controlled trial of sub anesthetic intravenous infusion of ketamine to treat lividopa induced diskincia in subjects with Parkinson's disease. In phase two clinical study is positive. The company will request a meeting with the FDA to discuss its plan and obtain an agreement to move to a phase three clinical study under the 505b2 regulatory pathway in the first half of 2022. So guys, this is a company that I think everyone needs to be aware of everyone needs to understand yes this news broke this morning and of course we're on top of the news because that's just what we do we break down the news we break it down first we make sure everyone is aware and if there's a stock that's an absolute rocket like pharma there has been from 18.5 cents to $1.24 that's a 10x right and that was in April so this is 10x this summer the question is will this continue right will this continue and is this dip after this huge move up a buying opportunity so once again pharma there at 88 cents and ph rm in canada in the united states ph rrf in the united states as you could see here we've been tracking this as it's been much lower and it's now in this really interesting zone so if you take the febinochis and you can see that this has been an absolute rocket and it's right now in the 61% zone in the fibs sitting right in the 61% retrace zone for the fibs so pretty decent retrace it might go a little lower the 50% zone before it bounces back because it doesn't seem to be moving yet so far today sometimes the market will have a little bit of a delayed reaction the big news let's do this again here let's take a look at the fibonacci extension let's just go yeah we'll go to the top here and then we'll just go down here to where it started so you can see it's sitting right in the 61% zone in canada in the united states which is typically a pretty interesting zone for retraces but sometimes we like we see a lot of stocks will tip down 50% from its highs so we could see it go a little bit lower before another big move up so very interesting position where it's trading right now all right let's just get back into that news so the catabit for treatment resistant depression the company has finalized the phase two clinical study protocol to evaluate catabit for treatment resistant depression the company is working with its scientific and clinical advisor dr marizio fava md with the aim to complete the ind and file it with the fda in early october with the overlap of the clinical operations from the parkinson's disease study company has already activated startup activities and identified potential clinical sites to screen and enroll patients for the proposed phase two clinical study in q4 2021 the aim is to share initial clinical results by the end of this year assuming the phase two clinical study is positive the company will request a meeting with the fda to discuss its plan and obtain an agreement to move to a phase three clinical study under the 505 b2 regulatory pathway in the first half of 2022 catabit is the company's patented combination formulation of fda-approved ketamine and butane as a potential next generation treatment for neural psychiatric disorders more than 300 million people suffer from major depression disorder and of those 100 million are resistant to available treatment worldwide catabit research has shown potential enhancement of the antidepressant effect while having the potential to significantly reduce the known negative side effects of ketamine side effects such as hallucinations confusion memory loss and abuse liability comprise the compliance and potential therapeutic value of ketamine ketamine for amyotrophic lateral sclerosis al s or lu garrick's disease now i must remind you guys that rich tv live is strictly for information education purposes please do your due diligence do your research before you invest in anything that we talk about here in rich tv live in saying that we've brought you this pic first it's been a big winner for our community congratulations to investors and this is a company that's just getting started i'm a huge fan of psychedelics for medicinal purposes just like kevin oliri who believes in the future of psychedelics i too also believe in the future of psychedelics and how we can help people especially in medicinal purposes so we absolutely love what pharma therapy holdings is doing here the company has been granted an orphan drug designation by the fda for ketamine to treat al s and along with its clinical advisors has finalized the phase 2 clinical study protocol the ind application for this study is in process and will be filed with the fda in october 2021 right around the corner with patients enrolling enrollment targeting q1 2022 pharma therapy has an exclusive license this is what makes them so special they have an exclusive license agreement with the university of kansas for the intellectual property protection and protecting the potential use of ketamine to treat al s pre clinical research has shown that the administration of ketamine preserves muscle functions in advancing al s and could potentially increase life expectancy when given in the early stages of muscle decline proprietary micro needle patch delivery programs for psychedelics pharma therapy is working with its research and development partners to advance next generation micro needle patches for the delivery of psychedelics hydro gel forming micro needle delivery technology for ketamine pharma therapy has exclusive worldwide this is huge development and commercial rights for the delivery of ketamine s ketamine and ketabet using a patented hydro gel forming micro needle patch companies working with professor ryan donnelly under a research agreement with the queen's university of velfast to develop the micro needle patch for the delivery of ketamine and ketabet fundamental research is almost complete and final research results will become available in december 2021 to date the initial proof of concept of ketamine and ketabet is very encouraging the company is currently preparing for validation and tech transfer activities to support phase one and phase two clinical studies in 2022 development progress will be made available as they arise for the remainder of the year the company's micro needle patch leverages the successful proof of concept achieved in delivering s ketamine the s plus initiator of innate enumer of ketamine via the micro needle patch which may overcome the drawbacks associated with ketamine administration in an intravenous or nasal spray format two details of the research can be found in a published paper titled hydro gel form forming micro needle arrays as a therapeutic option for transdermal s ketamine delivery what's next gel m a micro needle delivery technology for psychedelics guys i told you guys love this company love psychedelics yes we're early with psychedelics we're very early with psychedelics we know this but that's what we love to do here at rich dv live we love to bring you the winners and we love to bring them to first and that's exactly what we're doing here with pharma there that has so much work that they are doing and they're just getting started so the company is working with the terasaki institute under a research agreement to finalize the development of a proprietary micro needle delivery technology comprised of a biocompatible and biodegradable gelatin meth crylon gel m a composite for use with psychedelics such as psilocybin dmt mdma and lsd wow the gel patch delivery technology is the driving force of the company's psychedelics micro dicing program the research program is almost complete and successful proof of concept with psilocybin and lsd has been achieved wow full research results will be made available in november 2021 right around the corner the company is currently preparing for validation and tech transfer activities to support phase one and phase two clinical studies in 2022 clinical and commercial manufacturing and supply initiatives proprietary ketamine pharma there is focused on building a specialty ketamine based product pipeline the company has selected a us-based gmp contract development and manufacturing organization cdmo with extensive experience in the development production and supply of clinical and commercial controlled substance sterile products pharma that will work with the cdmo to develop the company's proprietary ketamine drug products to support future clinical studies and global commercial supply it is expected that the proprietary ketamine drug products will be available for phase three fda clinical studies and commercialization in hd 2022 proprietary micro needle patch companies entered into a co-development agreement with tsrl ink to jointly develop the patented hydrogel forming micro needle patch delivery technology this allows the companies to control the manufacturing and supply of micro needle patches for their respective clinical and commercial drug programs pharma there is focused on incorporating psychedelics and tsrl is focused on incorporating antiviral medications in a micro needle patch with the potential to improve the safety ie fewer side effects efficacy example bioavailability optimize dosing regimen including continuous system delivery and compliance for example storage distribution and self administration of these compounds that currently must be taken orally inhaled injected and intravenously recent activities included the tech transfer for scale up and manufacturing of clinical supplies to a gmp contract research lab and a pre-ind meeting with the fda that achieved agreement with the agency unproposed 505 b2 product development plans company aims to validate non-clinical and clinical production of the micro needle patch by october 2021 and begin non-clinical and clinical manufacturing supply at the end of 2021 company expects to enter into phase one and two clinical studies in 2022 to evaluate its micro needle patch in delivering ketamine ketabit trademark psilocybin dmt mdma and lsd wow guys pharma there are holdings everyone needs to be aware of this company right now ph rm in canada ph rrf in america it's been a huge winner and nobody even knows yet and when you think about everything that's coming this is just the start this is clearly just the start ph rm in canada ph rrf in america and you can see with the chart it's clearly been a huge winner for our community so who is pharma there holdings put them on your watches put them on your radar remember live strictly for information and education purposes please do your due diligence do your research before you invest anything that we talk about here on risk dv live always invest in the best the best is blessed and you absolutely deserve the best and we do our best to bring you guys the best companies the biggest news every single day so pharma there holdings limited is a clinical stage psychedelics biotech company told you guys we love psychedelics focused on the research development and commercialization of novel uses formulations and delivery methods of psychedelics including ketamine to treat mental health neurological and pain disorders pharma there is currently conducting an FDA approved phase two clinical study with ketamine to treat Parkinson's disease huge and is developing novel micro needle patches for the intradermal delivery of psychedelics you can follow them on twitter and link it in and their website which i showed you guys earlier is pharma there dot com and let's just try to see i can show you guys their website real quickly before we say goodbye super busy day here at rich tv live there it is so this is the website pharma there dot com you can see at the top home company research investors news and contact and you can get your investors deck right on the home page page learn about their focus recent press releases so clinic you know clearly lots and lots of news happening here with pharma there you can follow them on twitter just quickly go to their twitter which i am following and i'm hitting the bell for notifications only 462 followers guys and their investor deck is right there on twitter and their link it in page so their link it in page feel free to follow them on link it in hope you guys have a great trading week hope you have a great trading day remember rich tv live is strictly for information education purposes please do your diligence do your research before you invest anything that we talk about here on rich tv live and saying that i think this is a company it's undervalued under appreciated underexposed when you think about all of the catalysts coming for the company in the next few years the fact that psychedelics are still in the first inning that psychedelics are still looking for full blown fda approval on a medicinal scale i think that the future is bright for psychedelics not the only one i know kevin o'leary is a big fan of psychedelics i am as well love to know what you guys think comment on the video share the video everywhere if you like the video smash the like button comment down below as you're a bore rich from rich tv live and i'm out peace what do you guys think about the big news let me know what you guys think it's already been a rocket and i think it's just getting started let me know what you guys think you're a bore rich from rich tv live and i'm out peace